PDE10A-IN-32 is a potent, highly selective, brain penetrant PDE10A inhibitor with IC50 of 0.14 nM, displays no significant activity against other PDEs (IC50>1,000 nM)..

PDE10A-IN-31 is a potent, highly selective PDE10A inhibitor with IC50 of 2 nM for both rPDE10A and hPDE10A.

PD1-PD L1 inhibitor Polaris is a novel potent, small molecule inhibitor of PD-1/PD-L1 interaction (IC50=0.1-10 nM in ELISA assays) with anti-cancer activity.

PD1-IN-2 is a PD1 signaling pathway inhibitor, which acts as an immunomodulator.

PCSK9-IN-7l is a potent, small molecule PCSK9 mRNA translation inhibitor with IC50 of 1.37 uM, shows limited bone marrow toxicity (IC50=27.1 uM)..

PCSK9 modulator 10 is a highly potent, orally active PCSK9 modulator that inhibits PCSK9 production in HepG2 cells with IC50 of 0.036 nM.

PCI-33380 is an irreversible Bruton's Tyrosine Kinase (BTK) inhibitor (fluorescent probe).

PCARBTP is a derivative, potent, specific Kv1.3 channel inhibitor, reduces cell viability and efficiently kills B16F10 cancer cells at 1 uM.

PCAF BRD inhibitor L-45 is a potent, selective, and cell-active PCAF bromodomain inhibitor with Ki of 47 nM in HTRF assays, >4,500-fold selectivity over BRD4.

PC945 is a novel broad spectrum antifungal agent that potently inhibits Aspergillus fumigatus sterol 14α-demethylase (CYP51A and CYP51B) with IC50 of 0.23 and 0.22 uM, respectively.

PC1244 is a long acting fungicidal azole that targets A. fumigatus CYP51A and CYP51B, inhibits ergosterol synthesis in A. fumigatus with IC50 of 8 nM.

PBF509 (PBF-509, NIR 178) is a novel selective and potent Adenosine A2A Receptor (A2AR) antagonist, antagonizes A2AR agonist-mediated cAMP accumulation and impedance responses with KB values of 72.8 and 8.2 nM, respectively.

Paullinic acid is a long-chain fatty acid that has been detected in multiple biofluids, such as blood and urine.

PAT-1251 (PAT 1251, PAT1251) is a potent, selective and orally bioavailable lysyl oxidase-like 2 (LOXL2) inhibitor with IC50 of 0.71 uM in human whole blood assays, with high selectivity over LOX (400-fold) and other amine oxidases.

PARP14 inhibitor H10 (H10) is a potent, selective, cell-active PARP14 inhibitor with IC50 of 490 nM, with good selectivity over other PARPs (24-fold and 18-fold over PARP1 and TNKS1, respectively).

PARP11 inhibitor ITK7 (ITK7) is a potent and selective PARP11 inhibitor with IC50 of 14 nM, displays >200-fold selectivity over other PARPs.

PARP10 inhibitor 22 is a selective, cell-active inhibitor of PARP10 with IC50 of 1.8 uM, exhibits >10-fold selectivity over a large subset of other PARP family members.

Paradol(6-Paradol) is the active flavor constituent of the seeds of Guinea pepper (Aframomum melegueta); Paradol has been found to have antioxidative and antitumor promoting effects.

PAPTP is a PAP-1 derivative, potent, specific Kv1.3 channel inhibitor with IC50 of 31 nM in Jurkat T lymphocytes by patch-clamp, reduces cell viability and efficiently kills B16F10 cancer cells at 1 uM.

Papain is a cysteine protease of the peptidase C1 family, which is used in food, pharmaceutical, textile, and cosmetic industries.

pan-PIM inhibitor 17 is a potent, selective, orally available inhibitor of Pim kinase with IC50 of 0.8, 5.1 and 1.8 nM for Pim1, 2 and 3, respectively.

Pandacostat is the first nonselective HDAC inhibitor (pan-HDACi) with Ki of 0.12/0.07/0.95/0.18/0.032/1.1/0.5/1.4 uM for HDAC1/2/3/4/5/6/7/8/9, respectively.

Panadiplon (U-78875) is an anxiolytic drug with a novel chemical structure that is not closely related to other drugs of this type.

Pamidronic acid

Pamidronate Disodium

Palmostatin B is a potent Acyl protein thioesterase 1 (APT1.

Palmitelaidic acid is the trans isomer of palmitoleic acid. Palmitoleic acid is one of the most abundant fatty acids in serum and tissue.

Padsevonil (UCB-0942, UCB0942) is a potential anti-seizure agent that functions as a pre- and post-synaptic inhibitor..

Pactamycin (NSC 52947) is a potent protein synthesis inhibitor, inhibits protein synthesis at the translocation step on the 70S ribosome, has activity against Gram-positive and Gram-negative bacteria, and broad antitumor, antiviral, and antiplasmodial act

PAC1 (Compound PAC1) is a novel PROTAC antibody conjugate, more potent estrogen receptor-alpha (ERα) degrader compared to PROTAC without antibody conjugation..